| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
Aniracetam significantly enhances various concentrations of cisternic acid and counteracts cell death caused by glutamate, kainic acid, or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid. In primary cultures of cerebellar granule cells, ester and trans-1-aminocyclopentane-1,3-dicarboxylate also produce a neuroprotective response [4]. In cerebellar granule cell primary cultures, aniracetam improves phospholipase C's mGluR-coupled stimulation [4].
|
|---|---|
| ln Vivo |
Aniracetam (1 mM; 30-75 min) potentiates iQA receptors and greatly increases native synaptic transmission in rats [1]. Aniracetam (10-100 mg/kg; oral; single dosage) protects CO2-induced learning impairment in rats [2]. Aniracetam (30-300 mg/kg; oral; single dosage) increases the percentage of rats demonstrating passive avoidance [2].
|
| Animal Protocol |
Animal/Disease Models: Pyramidal neurons from male Wistar rats [1]
Doses: 1 mM Route of Administration: 30-75 minutes Experimental Results: Enhanced iQA receptors present in the brain and produced significant facilitation of native synaptic transmission . Animal/Disease Models: Male rat (100-120 g; pure CO2 induces hypercapnia) [2] Doses: 10, 30, 50 and 100 mg/kg Route of Administration: Oral; single dose (60 days before hypercapnia) minutes) Experimental Results: CO2-induced acquisition impairment was Dramatically prevented at doses of 30 and 50 mg/kg. Animal/Disease Models: Male rats and male mice (100-120 g and 21-25 g; 0.5 mg/kg scopolamine-induced transient memory impairment of passive avoidance procedures) [2] Doses: 30, 50, 100 and 300 mg/kg , Route of Administration: po; single dose Experimental Results: 2 hrs (hrs (hours)) after 50 and 100 mg/kg scopolamine, the percentage of rats showing passive avoidance increased Dramatically. |
| ADME/Pharmacokinetics |
Biological Half-Life
1-2.5 hours |
| References |
|
| Additional Infomation |
Aniracetam is a member of pyrrolidin-2-ones and a N-acylpyrrolidine.
Compound with anti-depressive properties used as a mental performance enhancer. Pharmacodynamics Aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems. |
| Molecular Formula |
C12H13NO3
|
|---|---|
| Molecular Weight |
219.2365
|
| Exact Mass |
219.089
|
| CAS # |
72432-10-1
|
| PubChem CID |
2196
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
399.7±34.0 °C at 760 mmHg
|
| Melting Point |
−58 °C(lit.)
|
| Flash Point |
195.5±25.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.574
|
| LogP |
0.27
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
282
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZXNRTKGTQJPIJK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3
|
| Chemical Name |
1-(4-methoxybenzoyl)pyrrolidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~456.12 mM)
H2O : ~0.33 mg/mL (~1.51 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5612 mL | 22.8061 mL | 45.6121 mL | |
| 5 mM | 0.9122 mL | 4.5612 mL | 9.1224 mL | |
| 10 mM | 0.4561 mL | 2.2806 mL | 4.5612 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
